- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04544215
A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection
A Clinical Study of Allogeneic Human Adipose-derived Mesenchymal Progenitor Cell Exosomes (haMPC-Exos) Nebulizer for the Treatment of Carbapenem-resistant Gram-negative Bacilli-induced Pulmonary Infection
Study Overview
Status
Conditions
Detailed Description
Pulmonary infection is a critical disease threatening human health. With the extensive use of antibiotics, the incidence of clinical drug resistance has been on the rise significantly in recent years. Once drug resistance occurs, we will see a high mortality rate due to scarce therapies and a poor prognosis. It is almost impossible to surmount the severe pulmonary infection caused by drug-resistant bacteria only by upgrading antibiotics. The commonly used supportive therapies clinically, such as glucocorticoids and immunomodulators, also lack forceful medical evidence. Therefore, it is urgent to explore new treatments.
Mesenchymal stem/progenitor cell exosomes are nano-sized vesicles secreted by mesenchymal stem/progenitor cells under certain conditions, which contain a lot of proteins, lipids and nucleic acids with tissue repair and immunomodulatory functions.
Mesenchymal stem/progenitor cell exosomes are nano-sized vesicles secreted by mesenchymal stem/progenitor cells under certain conditions, which contain a lot of proteins, lipids and nucleic acids with tissue repair and immunomodulatory functions.
Currently, it has been confirmed that stem cells can visibly improve the pathological changes of lungs caused by infection, lighten pulmonary edema, reduce protein exudation, mitigate alveolar inflammation, and remove bacteria. Thus, it brings new hope for the treatment of pulmonary infection caused by extensively drug-resistant bacteria.
Patients were treated, in the research project, with well-suited noninvasive haMPC-Exos aerosol inhalation, in an attempt to verify the efficacy and safety of haMPC-Exos treatment with pulmonary infection caused by gram-negative bacilli resistant to carbapenems.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Jieming Qu, MD,PhD
- Phone Number: +86-21-64370045
- Email: jmqu0906@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Recruiting
- Ruijin Hospital Shanghai Jiao Tong University School of Medicine
-
Contact:
- Jieming Qu, MD,PhD
- Phone Number: 0086-021-64370045
- Email: jmqu0906@163.com
-
Principal Investigator:
- Jieming QU, Ph.D., M. D.
-
Principal Investigator:
- Yinggang ZHU, Ph.D., M. D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1.Willingness of study participant to accept this treatment arm, and signed informed consent; 2.Male or female, aged at 18 years (including) to 75 years old; 3.Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), was diagnosed within 48 h. The diagnosis must simultaneously comply with the three clinical and radiological criteria described below, which occurred more than 2 d (48 h) after hospitalization, within 7 d after discharge (HAP) or at least 2 d (48 h) after mechanical ventilation (VAP):
The patients had at least one of the following clinical manifestations:
- New or deteriorating pulmonary symptoms or signs, such as cough, dyspnea, shortness of breath (e.g., respiratory rate higher than 25 beats/min), expectoration or need for mechanical ventilation;
- Hypoxemia (e.g., when subjects breathe room air at standard atmospheric pressure, the partial pressure of oxygen measured as lower than 60 mmHg by arterial blood gas [ABG], or the ratio of partial pressure of oxygen to fraction of inspired oxygen [PaO2/FiO2] deteriorated);
- According to the deterioration of oxygenation (ABG or PaO2/FiO2), the support system for the ventilator should be replaced urgently to strengthen oxygenation, or the positive end-expiratory pressure level should be changed;
- Aspirable respiratory secretions newly appeared;
The patients had at least one of the following signs:
- Confirmed fever (e.g., body temperature ≥ 38.4℃);
- Hypothermia (e.g., body temperature ≤ 35℃);
- Total peripheral white blood cell (WBC) count ≥ 11 × 109/L;
- Leukopenia, and total WBC ≤ 4 × 109/L;
- Immature neutrophils (rod-shaped nuclear cells) > 15% was observed on peripheral blood smears;
- The chest X-ray of the patients showed new or progressive infiltration, and pneumonia was considered.
4.The pathogenic test of the lower respiratory tract specimens revealed carbapenem-resistant Gram-negative bacilli (Pseudomonas aeruginosa, Klebsiella pneumoniae or Acinetobacter baumannii), which were consistent with the drug resistance spectrum and intermediate or resistant to all carbapenem antibiotics, namely, the minimum inhibitory concentration (MIC) of meropenem or imipenem ≥ 2 μg/ml (2 μg/ml was intermediate and 4 μg/ml was drug-resistant). The MIC of ertapenem ≥ 1 μg/ml, of which 1 μg/ml was intermediate and ≥ 2 μg/ml was drug-resistant.
Exclusion Criteria:
- 1.Patients with severe allergic constitution or positive skin test result for test products; 2.Confirmed or suspected community acquired pneumonia (CAP); 3.Confirmed or suspected pneumonia caused by mycoplasma, chlamydia, legionella, viruses, fungi or parasites; 4.HAP/VAP caused by obstruction, including lung cancer (or other malignant disease that causes lung obstruction) or other known obstructions; 5.Active immunosuppression, it is defined as receiving immunosuppressive drugs or under medical conditions associated with immunodeficiency. Including: 1) HIV (AIDS or CD4 < 200 cells/mm3); 2) received chemotherapy within 6 weeks before randomization; 3) immunosuppressive therapy, including maintenance glucocorticoid therapy (> 40 mg/day Prednisolone equivalent dose); 4) absolute neutrophil count < 500 mg/mm3; additional condition for inclusion: 1) Short-term (within one week) systemic (intravenous or oral) steroid therapy, using steroids for the treatment of skin disorders; 6.History of epilepsy and requirement for continuous anticonvulsant treatment or anticonvulsant treatment received within the last 3 years; 7.Undergoing hemodialysis or peritoneal dialysis; 8.Estimated or actual rate of creatinine clearance < 15 ml/min; 9.It is expected that any of the following drugs will be used during the study: Within 2 weeks before screening, or continuous use of valproic acid or divalproex sodium; 5-selective serotonin reuptake inhibitor, tricyclic antidepressant, 5-HT1 receptor agonist (triptans) or monoamine oxidase inhibitor; monoamine oxidase inhibitor (MAOIs) (or use of MAOIs within 2 weeks before screening) pethidine; buspirone; traditional Chinese medicine or herbal medicine; 10.Lung transplantation; 11.Bone marrow transplantation; 12.History of deep venous thrombosis or pulmonary embolism within the last 3 months; 13.Undergoing ECMO or high-frequency oscillatory ventilation support; 14.The estimated survival time <8 days; 15.HIV, viral hepatitis type B,viral hepatitis type C,or syphilis infection; 16.Period of pregnancy or lactation, or planned pregnancy within 6 months; 17.Incapable of understanding study protocol; 18.Any condition of unsuitable for the study determined by investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MPCs-derived exosomes Dosage 1
low-dose group
|
7 times aerosol inhalation of MPCs-derived exosomes (8.0*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
|
Experimental: MPCs-derived exosomes Dosage 2
high-dose group
|
7 times aerosol inhalation of MPCs-derived exosomes (16.0*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
|
Placebo Comparator: No exosomes
No MPCs-derived exosomes
|
No aerosol inhalation of MPCs-derived exosomes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Outcome Measures:
Time Frame: Up to 8 days
|
1.Clinical cure rate on the 8th d
|
Up to 8 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1.Bacterial clearance rate on the 8th d;
Time Frame: Up to 8 days
|
Bacterial clearance rate on the 8th d
|
Up to 8 days
|
2.Mortality on the 28th and 90th d;
Time Frame: Up to 28-90 days
|
Mortality on the 28th and 90th d
|
Up to 28-90 days
|
3.Recurrence rate after cure within 28 d;
Time Frame: Up to 28 days
|
Recurrence rate after cure within 28 d
|
Up to 28 days
|
4.Secondary infection rate of other pathogenic bacteria after cure within 28 d;
Time Frame: Up to 28 days
|
Secondary infection rate of other pathogenic bacteria after cure within 28 d
|
Up to 28 days
|
5.Duration of mechanical ventilation within 28 d;
Time Frame: Up to 28 days
|
Duration of mechanical ventilation within 28 d
|
Up to 28 days
|
6.Length of ICU stay (d) within 28 d;
Time Frame: Up to 28 days
|
Length of ICU stay (d) within 28 d
|
Up to 28 days
|
7.Incidence of adverse reactions at the end of treatment and 28 d after initial treatment.
Time Frame: Up to 28 days
|
Incidence of adverse reactions at the end of treatment and 28 d after initial treatment.
|
Up to 28 days
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MEXDR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug-resistant
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... and other collaboratorsActive, not recruitingTuberculosis | Multi Drug Resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Extensively Drug-Resistant Tuberculosis | Pre-XDR-TBSouth Africa
-
Centers for Disease Control and PreventionYale University; Columbia University; University of KwaZuluCompletedMulti-drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University Medical Center GroningenCompletedMultidrug-resistant Tuberculosis | Extensively Drug-resistant TuberculosisNetherlands
-
Mansoura University HospitalUnknown
-
University Hospital, GrenobleMinistry of Health, FranceTerminatedEpilepsy | Drug ResistantFrance
-
Nova Scotia Health AuthorityNot yet recruitingEpilepsy, Drug ResistantCanada
-
The Hospital for Sick ChildrenSt. Justine's HospitalCompletedEpilepsy, Drug ResistantCanada
Clinical Trials on Dosage 1 of MPCs-derived exosomes
-
Ruijin HospitalCellular Biomedicine Group Ltd.UnknownAcute Respiratory Distress SyndromeChina
-
Xuanwu Hospital, BeijingGuidon Pharmaceutics Ltd.Not yet recruitingAcute Ischemic Stroke
-
TC Erciyes UniversityRecruitingRetinitis PigmentosaTurkey
-
Jun ZhangXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...Active, not recruiting
-
University Of PerugiaRecruiting
-
Meissa Vaccines, Inc.CompletedRespiratory Syncytial Virus InfectionsUnited States
-
Meissa Vaccines, Inc.CompletedRespiratory Syncytial Virus InfectionsUnited States
-
Chinese Academy of Medical Sciences, Fuwai HospitalCompletedCardiac Surgery | HomeostasisChina
-
S.Biomedics Co., Ltd.Dt&SanomedicsActive, not recruitingCritical Limb IschemiaKorea, Republic of
-
Meissa Vaccines, Inc.RecruitingRespiratory Syncytial Virus (RSV)United States